Zacks Research Has Pessimistic Outlook of A FY2025 Earnings

Agilent Technologies, Inc. (NYSE:A) – Investment analysts at Zacks Research lowered their FY2025 EPS estimates for shares of Agilent Technologies in a research note issued on Friday, September 12th. Zacks Research analyst Team now forecasts that the medical research company will earn $5.57 per share for the year, down from their prior forecast of $5.58. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.58 per share. Zacks Research also issued estimates for Agilent Technologies’ Q4 2025 earnings at $1.58 EPS, Q1 2026 earnings at $1.38 EPS, Q2 2026 earnings at $1.39 EPS, Q3 2026 earnings at $1.48 EPS, Q4 2026 earnings at $1.66 EPS, FY2026 earnings at $5.91 EPS, Q1 2027 earnings at $1.56 EPS, Q2 2027 earnings at $1.55 EPS, Q3 2027 earnings at $1.63 EPS and FY2027 earnings at $6.49 EPS.

Several other research analysts have also issued reports on the stock. UBS Group dropped their price target on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating for the company in a research report on Thursday, May 29th. JPMorgan Chase & Co. cut their price target on shares of Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a research note on Thursday, May 29th. Wall Street Zen cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Friday, September 5th. Leerink Partners raised their price target on shares of Agilent Technologies to $135.00 and gave the stock a “buy” rating in a research note on Friday, May 30th. Finally, TD Cowen boosted their price target on shares of Agilent Technologies to $150.00 and gave the company a “buy” rating in a research report on Thursday, May 29th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Agilent Technologies has an average rating of “Moderate Buy” and an average target price of $140.08.

Agilent Technologies Stock Performance

A opened at $127.18 on Monday. The stock has a market cap of $36.06 billion, a PE ratio of 29.85, a P/E/G ratio of 3.91 and a beta of 1.24. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. Agilent Technologies has a 1 year low of $96.43 and a 1 year high of $153.84. The stock’s 50 day simple moving average is $120.01 and its 200-day simple moving average is $115.85.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business’s revenue was up 10.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS.

Insider Buying and Selling at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the business’s stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the sale, the chief executive officer directly owned 37,448 shares of the company’s stock, valued at $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Institutional Investors Weigh In On Agilent Technologies

Large investors have recently bought and sold shares of the company. Whipplewood Advisors LLC increased its stake in Agilent Technologies by 286.2% in the first quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 186 shares in the last quarter. Sunbelt Securities Inc. increased its stake in Agilent Technologies by 640.0% in the fourth quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 192 shares in the last quarter. Stone House Investment Management LLC bought a new stake in Agilent Technologies in the first quarter valued at approximately $30,000. Opal Wealth Advisors LLC bought a new stake in Agilent Technologies in the first quarter valued at approximately $31,000. Finally, Ransom Advisory Ltd bought a new stake in Agilent Technologies in the first quarter valued at approximately $32,000.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.